The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer

BACKGROUND: Current therapy for non-small-cell lung cancer (NSCLC) frequently includes immune checkpoint inhibitors, such as pembrolizumab, and programmed death ligand 1 (PD-L1) positivity is mandatory for its use in this setting. Vimentin plays a role in carcinogenesis through the activation of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bronte, Giuseppe, Puccetti, Maurizio, Petracci, Elisabetta, Landi, Lorenza, Cravero, Paola, Scodes, Simona, Ulivi, Paola, Ravaioli, Sara, Tumedei, Maria Maddalena, Burgio, Marco Angelo, Cappuzzo, Federico, Delmonte, Angelo, Crinò, Lucio, Bravaccini, Sara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130554/
https://www.ncbi.nlm.nih.gov/pubmed/34017688
http://dx.doi.org/10.3389/fonc.2021.669839

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8130554/
https://www.ncbi.nlm.nih.gov/pubmed/34017688
http://dx.doi.org/10.3389/fonc.2021.669839

Ejemplares similares